Nanopatch to tackle polio

The World Health Organization (WHO) is to provide funding to spin-out company, Vaxxas, so it can develop the NanopatchTM for polio vaccination. WHO will fund pre-clinical studies and the development of good manufacturing practices. Following the successful completion of this research, and all subsequent necessary clinical development and regulatory approvals, Vaxxas would have the opportunity to supply Nanopatches to help secure a lasting polio-free world. The development of the NanopatchTM has depended on AMMRF microscopy.

Polio was one of the most dreaded childhood diseases of the 20th century, resulting in limb disfigurement and irreversible paralysis in tens of millions of cases. As recently as 1988, more than 350,000 cases occurred every year in more than 125 endemic countries. Concerted efforts to eradicate the disease have reduced incidence by more than 99%, and efforts are being intensified to eradicate the remaining strains of transmission once and for all.

Related Stories
Microscopy for Medtech

MTPConnect helping us help medtech – Press Release

AMMRF Technical Voucher Fund receives funding from MTPConnect’s Project Fund Program Recognised as a big, bold idea to improve the productivity, competitiveness and innovative capacity of Australia’s medtech, biotech and pharmaceutical ...


Hazer Group live on ASX

Hazer Group was established in 2010 from technology developed at UWA to produce clean hydrogen and high-grade synthetic graphite from natural gas and iron ore. Its development depended on AMMRF microscopy @ UWA. They have announced the successful ...

burn victim

Fast-tracking elastin to market

Prof. Tony Weiss from the University of Sydney in conjunction with Elastagen Pty Ltd has been awarded a $1million Translation Award from the Wellcome Trust to fast track their elastin-based synthetic skin to clinical trials. They will refine and ...